Compare MARPS & PPBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MARPS | PPBT |
|---|---|---|
| Founded | 1956 | 2010 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.1M | 7.5M |
| IPO Year | N/A | N/A |
| Metric | MARPS | PPBT |
|---|---|---|
| Price | $4.38 | $0.83 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 5.7K | ★ 290.8K |
| Earning Date | 01-01-0001 | 11-14-2025 |
| Dividend Yield | ★ 7.84% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.31 | N/A |
| Revenue | ★ $965,040.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $13.98 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.34 | $0.53 |
| 52 Week High | $7.90 | $5.20 |
| Indicator | MARPS | PPBT |
|---|---|---|
| Relative Strength Index (RSI) | 52.53 | 53.10 |
| Support Level | $4.19 | $0.78 |
| Resistance Level | $4.33 | $0.89 |
| Average True Range (ATR) | 0.11 | 0.07 |
| MACD | 0.03 | 0.01 |
| Stochastic Oscillator | 47.20 | 68.67 |
Marine Petroleum Trust is a U.S based royalty trust. It provides administration and liquidation of rights to payments from oil and natural gas leases in the Gulf of Mexico. The Trust's subsidiary holds title to interests in properties which are situated offshore of Louisiana. The revenues of the trust are derived from the oil and natural gas production activities of third parties.
Purple Biotech Ltd is a clinical-stage company focused on advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, and to create treatments for people with cancer. Its oncology pipeline includes NT219: A dual inhibitor, small molecule that simultaneously targets Insulin Receptor Substrate 1 and 2 (IRS1/2) and Signal Transducer and Activator of Transcription (STAT3), two survival signal transduction pathways driving the development of cancer drug resistance. and CM24: is a humanized monoclonal antibody designed to block the interactions of Carcinoembryonic Antigen Related Cell Adhesion Molecule 1 (CEACAM1), a glycoprotein that plays a key role in immune regulation, cell adhesion, and tumor progression, CAPTN3.